- Previous Close
6.50 - Open
6.45 - Bid 5.31 x 100
- Ask 5.40 x 100
- Day's Range
5.59 - 6.45 - 52 Week Range
3.50 - 97.50 - Volume
65,174 - Avg. Volume
526,893 - Market Cap (intraday)
10.584M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-13.00 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
169.00
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
www.fsdpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: QNTM
View MorePerformance Overview: QNTM
Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QNTM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QNTM
View MoreValuation Measures
Market Cap
11.76M
Enterprise Value
9.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.12%
Return on Equity (ttm)
-63.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.47M
Diluted EPS (ttm)
-13.00
Balance Sheet and Cash Flow
Total Cash (mrq)
3.33M
Total Debt/Equity (mrq)
6.13%
Levered Free Cash Flow (ttm)
-9.99M